Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec (NASDAQ:EVO) announced on January 2, 2026 the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.
Dr. Fakih will lead a newly integrated Global Communications and Investor Relations function and report directly to CEO Dr. Christian Wojczewski to strengthen alignment, clarity and stakeholder engagement. The move follows the departure of Volker Braun, who led investor relations and ESG for five years. Dr. Fakih brings more than 15 years of life‑sciences experience and prior senior roles at QIAGEN, MorphoSys and CureVac, and holds a PhD in Chemistry.
Evotec (NASDAQ:EVO) closed the sale of Just - Evotec Biologics' Toulouse site to Sandoz, effective 05 December 2025, announced 08 December 2025.
The agreement includes approx. US$350m cash, upfront technology license fees for Evotec's continuous manufacturing platform, and potential additional license fees and success-based development revenues of more than US$300m, replacing existing contractual commitments. Total potential payments may exceed US$650m, plus royalties on up to 10 biosimilars (six tied to originator net sales of US$90bn).
Evotec says the deal is immediately earnings accretive and advances an asset-light strategy to improve revenue mix, margins, and capital efficiency while continuing development and manufacturing services in the U.S. and Europe.
Evotec (NASDAQ:EVO) confirmed that partner Bayer has initiated a Phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting Semaphorin-3A (Sema3A) for the treatment of Alport syndrome.
The randomized, double-blind, placebo-controlled Phase 2a ASSESS study with an extension phase will enroll participants aged 18 to 45. Under the 2016 collaboration, Evotec is eligible for a milestone payment upon first patient dosing, which Bayer expects in early 2026, and for further development and sales milestones plus tiered royalties if the program advances to commercialization.
Evotec (NASDAQ:EVO) announced receipt of a US$5 million milestone payment after the U.S. FDA accepted an Investigational New Drug (IND) application for a collaboration-developed CELMoD™ drug candidate.
The candidate, from Evotec's strategic protein degradation partnership with Bristol Myers Squibb initiated in 2018 and expanded in 2022, is expected to enter Phase 1 in 2026. The announcement highlights Evotec's multi-omics and AI-supported drug discovery role and frames the IND acceptance as a regulatory milestone validating the collaboration's progress toward first-in-class molecular glue degraders.
Evotec (NASDAQ:EVO) reported 9M 2025 results with group revenues €535.1m (down 7.1% YoY) and continued softness in early drug discovery (D&PD: €392.1m, -12.3%). Just - Evotec Biologics (JEB) accelerated, with revenues €143.4m, +11.3% and strong non-Sandoz/non-DoD growth. Adjusted Group EBITDA was a €(16.9)m) loss, with underutilization and fixed costs weighing on margins. After period-end, Evotec signed a >US$650m transaction with Sandoz (cash ~US$350m plus >US$300m in future payments) and expects royalties on up to ten biosimilars. Full-year 2025 guidance confirmed: revenues €760–800m; adj. EBITDA €30–50m; 2028 targets: CAGR 8–12% and adj. EBITDA margin >20%.
Evotec (NASDAQ:EVO) signed a sale and license agreement with Sandoz on November 4, 2025, transferring the Just - Evotec Biologics Toulouse site and granting an indefinite license to Evotec's continuous biologics manufacturing platform.
Key financial terms include approximately US$350m cash for the site, plus upfront license fees and success-based milestones totalling more than US$300m over coming years, and potential royalties on up to 10 biosimilars addressing an originator market > US$90bn. Closing is targeted for Q4 2025, subject to conditions including French FDI clearance. Company says the deal is immediately earnings accretive and supports an asset‑lighter strategy while confirming 2025 guidance and its 2028 outlook.
Evotec (NASDAQ:EVO) will announce its interim statement for the first nine months of 2025 on Wednesday, 05 November 2025.
The company will host an English-language conference call and webcast to discuss results and provide a performance update. The live audio webcast and presentation slides start at 2:00 pm CET (01:00 pm GMT, 08:00 am EST). Participants must register to receive dial-in details and access the slide presentation. An on-demand version of the webcast will be available later on Evotec's Financial Publications web page.
Evotec (NASDAQ: EVO) announced receipt of US$25 million from Bristol Myers Squibb (NYSE: BMY) on October 27, 2025 to support scientific progress in their strategic neuroscience partnership.
The collaboration, launched in 2016 and extended in 2023 for an additional eight years, focuses on discovering disease‑modifying treatments for neurodegenerative diseases. The joint pipeline includes EVT8683 (in‑licensed by BMS in 2021 as BMS‑986419), which has completed Phase 1 clinical trials. Evotec said the payment will advance further research and the partners' joint programs toward potential therapeutic options for patients with neurodegenerative conditions.
Evotec SE (NASDAQ:EVO) reported H1 2025 financial results showing mixed performance across segments. Group revenues declined 5% to €371.2 million, with Discovery & Preclinical Development (D&PD) revenues down 11% to €269.0 million due to soft market conditions. However, Just - Evotec Biologics (JEB) showed strong growth of 16% reaching €102.2 million.
The company announced significant progress in strategic collaborations, including US$75 million in payments from Bristol Myers Squibb for protein degradation achievements and US$20 million for neuroscience research. Additionally, Evotec signed a non-binding agreement to sell its J.POD biologics facility in Toulouse for approximately US$300 million, marking a strategic shift towards an asset-lighter model.
For full-year 2025, Evotec expects revenues of €760-800 million and adjusted EBITDA of €30-50 million.
Evotec SE (NASDAQ:EVO) has scheduled the release of its first half-year 2025 financial results for Wednesday, August 13, 2025. The company will host a conference call and webcast at 2:00 PM CEST to discuss the results and provide a business update.
The presentation will be conducted in English and will be accessible via both audio webcast and phone conference. Participants joining by phone must pre-register to receive dial-in details. Presentation slides will be available for both webcast viewers and phone participants, and an on-demand version will be accessible on Evotec's website after the event.